Indofarma and Quantum Laboratories Establish Cooperation in Production and Marketing to Drive Sales Performance

Taking place at the Head Office of PT Indofarma Tbk, West Cikarang, Friday 26 May 2023, a Toll Manufacturing Cooperation Agreement was signed between PT Indofarma Tbk and PT Quantum Laboratoris Internasional as a form of B2B partnership, especially in utilizing the capacities and capabilities of each company so that grow better. This cooperation agreement was signed by the Production & Supply Chain Director of PT Indofarma Tbk, Jejen Nugraha and the Director of PT Quantum Laboratoris Internasional, Veronica Susi Setyaningsih. During the signing of this collaboration, the Main Director of PT Indofarma Tbk, Agus Heru Darjono, said that with the collaboration between PT Indofarma Tbk and PT Quantum Laboratoris Internasional, it is expected to increase the production utility of PT Indofarma Tbk and on the one hand will encourage PT Quantum Laboratoris Internasional to achieve market share as expected. This is in line with the statement of the Main Director of PT Quantum, Edwin Tjahyadi who was also present to witness the signing of this Cooperation, “PT Quantum has a team and marketing network spread across Indonesia and our focus is that the level of product availability must be well maintained to meet market needs,” said Edwin . Both of them believe that with their capabilities, this collaboration will significantly increase the sales performance of the two companies. Not only that, Agus Heru also emphasized that Indofarma always makes the quality of Indofarma’s drug production a top priority. Until now, PT Indofarma Tbk’s production facilities have been certified as Good Manufacturing Practices (GMP) and Good Manufacturing Practices for Traditional Medicines (CPOTB) from the Food and Drug Monitoring Agency (BPOM) and ISO 9001: 2015 Quality Management System certification. Through a series of quality control and assurance processes, Indofarma’s medicinal syrup products have complied with the requirements and are safe for consumption by the public as long as they comply with the rules for use, as stated in the explanation BPOM RI Number HM.01.1.2.05.23.75 dated 12 May 2023. So that this collaboration can increase the availability of quality medicines for a better degree of health for Indonesian people.